• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺腺癌伴神经内分泌分化:分子标志物检测与治疗结局。

Lung adenocarcinoma with neuroendocrine differentiation: Molecular markers testing and treatment outcomes.

机构信息

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, National Taiwan University Hsin-Chu Branch, Biomedical Park Hospital, No. 2, Section 1, Shengyi Road, Zhubei City, Hsinchu County 302, Taiwan.

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, No. 7, Chung-Shan South Road, Taipei 100225, Taiwan.

出版信息

J Formos Med Assoc. 2023 Aug;122(8):731-737. doi: 10.1016/j.jfma.2022.12.011. Epub 2022 Dec 30.

DOI:10.1016/j.jfma.2022.12.011
PMID:36586785
Abstract

BACKGROUND

Among the histologic types of lung cancer, adenocarcinoma is the most common. Moreover, lung adenocarcinoma with neuroendocrine differentiation (LANED) is a rare histologic character. So far, the clinical significance remains unclear.

MATERIAL AND METHODS

We searched for the patients diagnosed with LANED from the electronic pathology database between January 2000 and June 2020 in a tertiary hospital. The tumor specimens were reviewed by a pathologist to confirm the diagnosis. EGFR mutation, ALK translocation, as well as programmed death ligand 1 (PD-L1) and rearranged during transfection (RET) expression were tested in the specimens of LANED. The clinical data were also collected and analyzed.

RESULTS

A total of 10 patients diagnosed with LANED were included. Most were male (80%) and ever smokers (70%). The median age was 71.5 years old. At diagnosis, most had tumors harboring no EGFR mutation (70%), negative ALK translocation (88.9%), and without PD-L1 expression (90%). All specimens tested by immunohistochemical staining for RET expression (n = 9) showed positive results. Among the 10 patients, five underwent operation (stage I, n = 4; stage II, n = 1). The patient with stage II disease had recurrence 11 months later. For patients with advanced stages (stage III, n = 1; stage IV, n = 4), the treatment modalities varied and the overall survival ranged from 11.0 to 46.7 months.

CONCLUSION

LANED might be associated with a high proportion of RET expression, whereas EGFR mutation, ALK alteration, and PD-L1 expression were uncommon. Further large-scale prospective studies on molecular testing profile and clinical significance of LANED are warranted.

摘要

背景

在肺癌的组织学类型中,腺癌最为常见。此外,具有神经内分泌分化的肺腺癌(LANGED)是一种罕见的组织学特征。到目前为止,其临床意义尚不清楚。

材料与方法

我们在一家三级医院的电子病理数据库中搜索了 2000 年 1 月至 2020 年 6 月期间诊断为 LANGED 的患者。由病理学家对肿瘤标本进行复查以确认诊断。对 LANGED 标本进行 EGFR 突变、ALK 易位以及程序性死亡配体 1(PD-L1)和转染重排(RET)表达检测。同时收集并分析临床资料。

结果

共纳入 10 例诊断为 LANGED 的患者。大多数为男性(80%)和既往吸烟者(70%)。中位年龄为 71.5 岁。诊断时,大多数肿瘤无 EGFR 突变(70%)、ALK 易位阴性(88.9%)且无 PD-L1 表达(90%)。所有进行 RET 免疫组织化学染色检测的标本(n=9)均显示阳性结果。10 例患者中,5 例行手术治疗(Ⅰ期,n=4;Ⅱ期,n=1)。Ⅱ期疾病患者 11 个月后复发。对于晚期患者(Ⅲ期,n=1;Ⅳ期,n=4),治疗方式各异,总生存期为 11.0-46.7 个月。

结论

LANGED 可能与较高比例的 RET 表达相关,而 EGFR 突变、ALK 改变和 PD-L1 表达并不常见。进一步开展关于 LANGED 分子检测谱和临床意义的大规模前瞻性研究是必要的。

相似文献

1
Lung adenocarcinoma with neuroendocrine differentiation: Molecular markers testing and treatment outcomes.肺腺癌伴神经内分泌分化:分子标志物检测与治疗结局。
J Formos Med Assoc. 2023 Aug;122(8):731-737. doi: 10.1016/j.jfma.2022.12.011. Epub 2022 Dec 30.
2
Clinical relevance of PD-L2 expression in surgically resected lung adenocarcinoma.手术切除肺腺癌中 PD-L2 表达的临床意义。
Lung Cancer. 2022 Jun;168:50-58. doi: 10.1016/j.lungcan.2022.04.011. Epub 2022 Apr 22.
3
Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma.程序性死亡配体 1 表达及其与手术切除肺腺癌的临床病理特征、预后和驱动癌基因突变的关系。
Lung Cancer. 2021 Nov;161:163-170. doi: 10.1016/j.lungcan.2021.09.011. Epub 2021 Sep 20.
4
Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.EGFR、ALK或ROS1中经典驱动癌基因突变与肺腺癌中22C3-PD-L1≥50%表达之间的相关性
J Thorac Oncol. 2017 May;12(5):878-883. doi: 10.1016/j.jtho.2016.12.026. Epub 2017 Jan 16.
5
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib.程序性死亡配体 1 表达与克唑替尼治疗间变性淋巴瘤激酶阳性肺腺癌患者融合变异及临床结局的相关性。
Oncologist. 2020 Aug;25(8):702-711. doi: 10.1634/theoncologist.2020-0088. Epub 2020 May 13.
6
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.表皮生长因子受体(EGFR)突变和间变性淋巴瘤激酶(ALK)重排与非小细胞肺癌中PD-1通路阻断的低反应率相关:一项回顾性分析
Clin Cancer Res. 2016 Sep 15;22(18):4585-93. doi: 10.1158/1078-0432.CCR-15-3101. Epub 2016 May 25.
7
Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma.程序性死亡配体1表达与手术切除肺腺癌的分子特征相关。
J Transl Med. 2016 Jun 24;14(1):188. doi: 10.1186/s12967-016-0943-4.
8
Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.基于下一代测序的肺癌分子诊断特征及其与 PD-L1 表达的关系。
Pathol Res Pract. 2020 Feb;216(2):152797. doi: 10.1016/j.prp.2019.152797. Epub 2019 Dec 23.
9
PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements.肺腺癌中 EGFR 突变或 ALK 重排患者的 PD-L1 表达。
Lung Cancer. 2018 Apr;118:36-40. doi: 10.1016/j.lungcan.2018.01.024. Epub 2018 Feb 2.
10
mRNA expression of programmed cell death ligand 1 and components of the phosphatidylinositol 3-kinase/AKT/phosphatase and tensin homolog pathway in epidermal growth factor receptor mutation-positive lung adenocarcinoma.程序性细胞死亡配体1的mRNA表达以及磷脂酰肌醇3激酶/蛋白激酶B/张力蛋白同源物通路各组分在表皮生长因子受体突变阳性肺腺癌中的表达
J Cancer Res Ther. 2019;15(4):914-920. doi: 10.4103/jcrt.JCRT_636_18.

引用本文的文献

1
Unveiling prognostic factors and predictive modeling in lung adenocarcinoma with neuroendocrine differentiation.揭示具有神经内分泌分化的肺腺癌的预后因素和预测模型。
Transl Cancer Res. 2025 Aug 31;14(8):4649-4661. doi: 10.21037/tcr-2025-12. Epub 2025 Aug 22.
2
ciRS-7 expression is epigenetically regulated in cancer cells across human adenocarcinomas.在人类腺癌的癌细胞中,ciRS-7的表达受表观遗传调控。
PLoS Genet. 2025 Jun 2;21(6):e1011726. doi: 10.1371/journal.pgen.1011726. eCollection 2025 Jun.
3
Comparative efficacy of sugammadex and neostigmine in postoperative nausea and vomiting management: a meta-analysis of randomized controlled trials.
舒更葡糖钠与新斯的明在术后恶心呕吐管理中的比较疗效:一项随机对照试验的荟萃分析
J Anesth. 2025 Apr 28. doi: 10.1007/s00540-025-03498-7.
4
Treating a Non-mixed Neuroendocrine Colorectal Tumor Under Mixed Neuroendocrine Neoplasm (MiNEN) Protocols: A Case Report of Successful Outlier Management.在混合性神经内分泌肿瘤(MiNEN)方案下治疗非混合性神经内分泌结直肠肿瘤:成功处理异常病例的一例报告
Cureus. 2025 Feb 20;17(2):e79389. doi: 10.7759/cureus.79389. eCollection 2025 Feb.
5
Remarks on Selected Morphological Aspects of Cancer Neuroscience: A Microscopic Photo Review.癌症神经科学某些形态学方面的述评:显微照片综述
Biomedicines. 2024 Oct 14;12(10):2335. doi: 10.3390/biomedicines12102335.
6
Survival comparison of pulmonary neuroendocrine carcinoma, adenocarcinoma with neuroendocrine differentiation, and adenocarcinoma.肺神经内分泌癌、伴有神经内分泌分化的腺癌及腺癌的生存比较
J Thorac Dis. 2024 Jan 30;16(1):604-614. doi: 10.21037/jtd-23-1811. Epub 2024 Jan 17.